IDXX on Nasdaq

IDEXX Laboratories, Inc.

Logo: http://www.idexx.com/, Public domain, via Wikimedia Commons4

American multinational corporation

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

1983Founded1

Compare with Quidel, Lantheus Holdings, Inc. or NeoGen, or pick any stock.

  • TickerIDXX on Nasdaq1
  • Industryhealth care1
  • HeadquartersWestbrook1
  • Websitewww.idexx.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business addressOne Idexx Drive, Westbrook, Me 04092-20415
  • Filer categoryLarge accelerated filer5

See how the biggest companies compare on our leaderboards

IdexxLaboratoriesMarkham
Photo: Raysonho @ Open Grid Scheduler / Scalable Grid Engine, CC0, via Wikimedia Commons7

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions (as of 2025).3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

61.8%Gross margin8
31.6%Operating margin8
24.6%Net margin8
10.4%Revenue growth, 20258
66.0%Return on equity8
0.23×Debt to equity8
$1.1BFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 59% of the revenue IDEXX Laboratories, Inc. broke down this way in fiscal 2025.

  1. Product$2.5B859%up 13% from 2024
  2. Service$1.8B841%up 7% from 2024
Products and services by year
Products and services202320242025
Product$2.1B$2.2B$2.5B
Service$1.6B$1.6B$1.8B

Business segments

Companion Animal Group brought in 92% of the revenue IDEXX Laboratories, Inc. broke down this way in fiscal 2025.

  1. Companion Animal Group$4.0B892%up 11% from 2024
  2. Water$201.1M85%up 9% from 2024
  3. Livestock And Poultry Diagnostics$131.8M83%up 8% from 2024
Business segments by year
Business segments202320242025
Companion Animal Group$3.4B$3.6B$4.0B
Water$168.1M$185.1M$201.1M
Livestock And Poultry Diagnostics$121.7M$122.1M$131.8M

Regions

United States brought in 66% of the revenue IDEXX Laboratories, Inc. broke down this way in fiscal 2025.

  1. United States$2.8B866%up 9% from 2024
  2. Europe, the Middle East, and Africa, Other$230.0M85%up 17% from 2024
  3. Germany$206.8M85%up 19% from 2024
  4. Canada$167.3M84%up 9% from 2024
  5. United Kingdom$154.4M84%up 15% from 2024
  6. France$126.0M83%up 14% from 2024
  7. Asia Pacific, Other$124.4M83%up 13% from 2024
  8. Australia$112.2M83%up 10% from 2024
  9. Latin America and Caribbean$90.4M82%up 8% from 2024
  10. Japan$83.4M82%up 14% from 2024
  11. Spain$71.0M82%up 15% from 2024
  12. Italy$66.9M82%up 15% from 2024
Regions by year
Regions202320242025
United States$2.4B$2.5B$2.8B
Europe, the Middle East, and Africa, Other$176.4M$196.3M$230.0M
Germany$149.8M$173.7M$206.8M
Canada$150.1M$152.9M$167.3M
United Kingdom$121.7M$134.6M$154.4M
France$96.8M$110.8M$126.0M
Asia Pacific, Other$104.1M$110.1M$124.4M
Australia$95.5M$102.0M$112.2M
Latin America and Caribbean$83.9M$83.7M$90.4M
Japan$75.6M$73.1M$83.4M
Spain$52.3M$61.9M$71.0M
Italy$53.8M$58.2M$66.9M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue38¢$1.6B
  • Research and development6¢$251.2M
  • Other costs25¢$1.1B
  • Income tax6¢$264.7M
  • Profit25¢$1.1B

Out of $4.3B in revenue.8

Where each dollar of operating cash went, fiscal 2025

  • Capital spending9¢$124.7M
  • Share buybacks91¢$1.2B

Out of $1.2B of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.8

Financial statements

Revenue91011128$4.3B in 2025+79% since 2019
0$2.0B$4.0B$6.0B2019: $2.4B$2.4B20192020: $2.7B$2.7B2020+12%2021: $3.2B$3.2B2021+19%2022: $3.4B$3.4B2022+5%2023: $3.7B$3.7B2023+9%2024: $3.9B$3.9B2024+6%2025: $4.3B$4.3B2025+10%
Gross profit91011128$2.7B in 2025+95% since 2019
0$1.0B$2.0B$3.0B2019: $1.4B$1.4B20192020: $1.6B$1.6B2020+15%2021: $1.9B$1.9B2021+20%2022: $2.0B$2.0B2022+6%2023: $2.2B$2.2B2023+9%2024: $2.4B$2.4B2024+9%2025: $2.7B$2.7B2025+12%
Operating income91011128$1.4B in 2025+146% since 2019
0$500.0M$1.0B$1.5B2019: $552.8M$552.8M20192020: $694.5M$694.5M2020+26%2021: $932.0M$932.0M2021+34%2022: $898.8M$898.8M2022−4%2023: $1.1B$1.1B2023+22%2024: $1.1B$1.1B2024+3%2025: $1.4B$1.4B2025+21%
Net income91011128$1.1B in 2025+148% since 2019
0$500.0M$1.0B$1.5B2019: $427.7M$427.7M20192020: $581.8M$581.8M2020+36%2021: $744.8M$744.8M2021+28%2022: $679.1M$679.1M2022−9%2023: $845.0M$845.0M2023+24%2024: $887.9M$887.9M2024+5%2025: $1.1B$1.1B2025+19%

Every line of the income statement in the latest annual report, as filed.8

Period ending2025-12-312024-12-312023-12-31
Total revenue$4.3B$3.9B$3.7B
Total cost of revenue$1.6B$1.5B$1.5B
Gross profit$2.7B$2.4B$2.2B
Sales and marketing$643.5M$588.5M$566.1M
General and administrative$404.8M$442.3M$335.8M
Research and development$251.2M$219.8M$191.0M
Total operating expenses$1.3B$1.3B$1.1B
Income from operations$1.4B$1.1B$1.1B
Interest expense-$38.9M-$31.2M-$41.6M
Interest income$3.0M$12.7M$5.6M
Income before provision for income taxes$1.3B$1.1B$1.1B
Provision for income taxes$264.7M$222.0M$216.1M
Net income$1.1B$887.9M$845.0M
Basic (in USD per share)$13.17$10.77$10.17
Diluted (in USD per share)$13.08$10.67$10.06
Basic (in shares)80.4M shares82.5M shares83.1M shares
Diluted (in shares)81.0M shares83.2M shares84.0M shares

Compare IDEXX Laboratories, Inc. with another company

Leadership

Who has led IDEXX Laboratories, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jonathan W. Ayers2006–2019
  2. Jay Mazelsky2019–now

Chair

  1. Jonathan W. Ayers2006–2019

President

  1. Jonathan W. Ayers2006–2019
  2. Jay Mazelsky2019–now

Chief financial officer

  1. Merilee Raines2006–2013
  2. Willard R. Blanche Jr.2013
  3. Brian P. McKeon2014–2025
  4. Andrew Emerson2025–now
1990200020102020
Board members and other officers (48)

Products and brands

Companion Animal Group

The Companion Animal Group (CAG) provides in-clinic laboratory analyzers for companion animals. Analyzers measure blood cell counts as well as levels of certain enzymes in blood or urine for the purpose of monitoring health conditions. Major products of this segment are the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, Symmetric dimethylarginine (SDMA), ProCyte Dx Hematology Analyzer, the LaserCyte Hematology Analyzer, the IDEXX VetAutoread Hematology Analyzer, the SNAP Pro analyzer, and so on, among other laboratory equipment and analytical services.

Water testing

The Water segment provides products to measure microbiological parameters in water. Popular products of this segment include Colilert, Colilert-18, and Colisure for detecting total coliform and E. coli. Water products are sold in over 120 countries around the globe.

Livestock and Poultry Diagnostics

The Livestock and Poultry Diagnostics division provides products to detect diseases in livestock and poultry. Products of this segment include tests for avian influenza, bovine viral diarrhoea virus, porcine reproductive and respiratory syndrome (PRRS), and bovine spongiform encephalopathy (BSE or mad cow disease).

From Wikipedia’s article on Idexx Laboratories, shared under CC BY-SA 4.0.6

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Timeline

  1. Aug 7, 2019New chief executive Jay Mazelsky becomes CEO16
  2. Feb 15, 2006New chief executive Jonathan W. Ayers becomes CEO17
  3. 1983Founded Founded1

Recent filings

  1. Sep 9, 20264
  2. Sep 4, 2026144
  3. Aug 24, 20264
  4. Aug 4, 20268-K
  5. Aug 4, 202610-Q
  6. Aug 3, 20264
  7. Jun 2, 20264
  8. Jun 1, 2026SD
  9. May 20, 2026144
  10. May 15, 20268-K
  11. May 14, 20264
  12. May 14, 20264
  13. May 14, 20264
  14. May 14, 20264
  15. May 14, 20264

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69